<DOC>
	<DOCNO>NCT01738152</DOCNO>
	<brief_summary>The purpose study see whether feasible conduct study determine use hyaluronic acid ( HLA ) vaginal gel ( HyaloGYN® ) improve vulvovaginal health . This study aim look whether HyaloGYN® effective woman history hormone receptor positive cancer experience vaginal and/or vulvar symptom estrogen deprivation follow breast endometrial cancer treatment .</brief_summary>
	<brief_title>Non-Hormonal Vaginal Moisturizer Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms Vulvovaginal Health</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>History breast cancer endometrial cancer confirm MSKCC outside pathology report Breast cancer patient must least 3 month postactive treatment ( include chemotherapy , radiation therapy , endocrine therapy , and/or maintenance therapy ) , great 5 year postactive treatment ( exception : AIs require , monoclonal antibody allow ) Breast cancer patient must currently adjuvant aromatase inhibitor Endometrial cancer patient must least 3 month postactive chemotherapy and/or maintenance therapy treatment great 5 year postactive chemotherapy and/or maintenance therapy treatment . They must least 4 week postradiation therapy ( EBRT IVRT ) great 5 year postradiation therapy . Endometrial cancer patient must undergo surgical treatment ( total abdominal hysterectomy ( [ TAH ] /BSO ) ) radiation therapy ( external beam radiation therapy [ EBRT ] IVRT ) Currently clinical evidence disease Menopausal study entry describe : Surgical menopause ( TAH/BSO ) , Age ≥ 50 year cessation menstruation least 1 year , Age &lt; 50 year cessation menstruation least 1 year estradiol level postmenopausal range , Rendered postmenopausal use LHRH agonist Patients new visit Female Sexual Medicine Program patient consistently use vulvovaginal health promotion strategy ( e.g. , pelvic floor exercise , dilator therapy , moisturizers ) recommend Female Sexual Medicine Program Reporting bother vulvovaginal symptom estrogen deprivation ( i.e. , vulvovaginal dryness discomfort [ pain intercourse examination ] ) Without history cancer ( exclude nonmelanoma skin cancer ) Women least 18 year age Able read speak English Able participate informed consent process Inability provide inform consent Vaginal bleeding unknown etiology within 12 month study entry Currently take hormone replacement therapy [ local systemic ] ( Patients must discontinue 2 week order eligible prior study enrollment )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HYALOGYN VAGINAL GEL</keyword>
	<keyword>vaginal dryness</keyword>
	<keyword>12-232</keyword>
</DOC>